Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study

• Egile Nagusiak: Frédéric Debellut (Egilea), Clint Pecenka (Egilea), William P. Hausdorff (Egilea), Andrew Clark (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

While current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea everywhere, their effectiveness is lower in high burden settings. Alternative approaches are in advanced stages of clinical development, including injectable next-generation rotavirus vaccine (iNGRV) candidates, which h...